Especially in situations where local, sustained delivery of protein therapeutics is ideal for positive treatment outcomes, such as the delivery of anti-VEGF antibodies to the retina for treating diabetic retinopathy, the local delivery of chemotherapeutics to a tumor, or the local treatment of rheumatoid arthritis. This evidence concerns the gene VEGFA and rheumatoid arthritis.